Market Pulse
GlaxoSmithKline's new severe asthma treatment gets FDA approval
GlaxoSmithKline’s Nucala (mepolizumab) drug has received approval from the US Food and Drug Administration (FDA) for its Biologics License Application.
Tate & Lyle sweetens investors with growth in interim profit
Food ingredients maker Tate & Lyle posted an increase in interim profit, marking a first improvement in trading after a turbulent end to 2014.
easyJet sees 10% year-on-year increase in passenger numbers
easyJet had nearly 6. 4m passengers booked on its flights in October.
Randgold Resources third quarter profit slips despite record production
Randgold Resources posted reported a decline in third-quarter profit despite a rise to record production levels.
Morrisons sales deflate, while AstraZeneca inflates revenue guidance
London open The FTSE 100 is expected to open 11 points higher on Thursday morning, according to sources in the City of London.
London pre-open: MPC, central banks in focus
Investors were anxious ahead of Thursday´s meeting of the Monetary Policy Committee given the more 'hawkish' tone adopted by US Federal Reserve chairwoman Janet Yellen on the previous day.
RSA nine-month premium income nudges up 1%, turnaround on track
RSA Insurance booked a net loss of £16m in the third quarter as a result of the earthquake in Chile, but insisted its turnaround plan is on track as it posted a 1% rise in underlying premium income in the first nine months of the year.
Thursday newspaper round-up: Volkswagen, Facebook, RBS, Brexit
Volkswagen needs to tear up its complex corporate governance structure in the wake of the emissions scandal that knocked a further 10 per cent off its share price on Wednesday, according to investors and governance experts. They called for a radical overhaul that would involve the families, state government and sovereign wealth fund that are the carmaker’s biggest shareholders all giving up seats on its supervisory board. – Financial Times.